NASDAQ$RXRX
Recursion Pharmaceuticals Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Headline financials
Revenue & EPS history
Recursion Pharmaceuticals · Revenue · Quarterly
$2.56M
Q1 2021+4,170%vs Q1 2020
Revenue by segment
Recursion Pharmaceuticals · $2.5M total across 1 segment · Q1 2021
- Collaboration Revenue$2.5M—100.0%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports
-3.1%
Avg return
Earnings day
-0.4%
Avg return
5 days after
+7.2%
Avg return
30 days after
32%
8 / 25 earnings
Positive
+11.6%
Q1 2023
Best reaction
-16.5%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.8% | -3.3% | -1.8% | |
| Q4 2025 | +6.5% | +2.8% | -16.7% | |
| Q3 2025 | -0.6% | -9.8% | -5.8% | |
| Q1 2025 | -16.5% | -24.0% | -13.9% | |
| Q4 2024 | -12.3% | -16.9% | -29.6% | |
| Q3 2024 | +1.6% | +15.0% | +17.4% | |
| Q2 2024 | -1.3% | +2.7% | -7.1% | |
| Q1 2024 | +0.1% | +17.0% | -0.9% | |
| Q4 2023 | -12.3% | -13.2% | -32.5% | |
| Q3 2023 | -3.0% | +14.7% | +35.0% | |
| Q2 2023 | -0.5% | -13.2% | -24.2% | |
| Q1 2023 | +11.6% | +2.5% | +75.8% | |
| Q4 2022 | +7.1% | +11.4% | -11.3% | |
| Q3 2022 | +8.9% | +32.8% | -0.6% | |
| Q2 2022 | +4.4% | +27.4% | +35.8% | |
| Q1 2022 | -9.4% | +1.4% | +34.4% | |
| Q4 2019 | -0.7% | -1.7% | -14.2% | |
| Q4 2021 | -0.7% | -1.7% | -14.2% | |
| Q3 2020 | -9.1% | -4.3% | -3.2% | |
| Q3 2021 | -9.1% | -4.3% | -3.2% | |
| Q2 2020 | -10.8% | -17.2% | +23.1% | |
| Q2 2021 | -10.8% | -17.2% | +23.1% | |
| Q1 2020 | -7.1% | -3.6% | +37.8% | |
| Q1 2021 | -7.1% | -3.6% | +37.8% | |
| Q4 2020 | -7.1% | -3.6% | +37.8% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro